ZİYA SALİHOĞLU, Şener DEMİROLUK, Yıldız KÖSE

Morbid obez hastalarda cisatrakuryumun nöromusküler iletime etkileri

Bu çalışmada normal ağırlıklı ve morbid obez olgularda cisatrakuryumun nöromusküler iletime etkileri karşılaştırıldı. Olgular morbid obez grubu (n=20) ve kontrol grubu (n=20) olarak ikiye ayrıldı. Morbid obez olgularda ilaç dozları düzeltilmiş ağırlığa göre verildi. Cisatrakuryum 0.15 mg kg-1 dozda verildi. TOF'a göre; T0 (etki başlama süresi), T25 (T1'in % 25 geri döndüğü zaman), T25-75 (T25'in T75'e ulaştığı zaman) kaydedildi. Vücut kitle indeksi morbid obez ve kontrol grubunda sırası ile 55 ±5 kg m-2, 22+4 kg m-2 olarak belirlendi. T0 zamanı morbid obez ve kontrol grubunda sırası ile 177±23 sn, 168 ±19 sn olarak belirlendi. T25 morbid obez ve kontrol grubunda sırası ile 46±7 dk, 56±8 dk olarak belirlendi (p

Anahtar Kelimeler:

İlaç uygulama programı, Atrakuriyum, Nöromüsküler blokaj, Obezite, morbid, Vücut kitle indeksi, Entübasyon

Neuromuscular effects of cisatracurium in morbidly obese patients

In this study, the neuromuscular effects of cisatracurium were compared between morbidly obese and normal weight patients. Morbidly obese patients are named morbidly obese group (n=20), and normal patients are named control group (n=20). In the morbidly obese group, corrected weight was used to calculate the drug doses. 0.15 mg kg-1 cisatracurium was administered. T0 (onset time), T25 (25 % recovery of T1), T25-75 (time of T25 to T75) time of according to TOF was recorded. Body mass index values were found to be 55±5 kg m-2, 22±4 kg m-2 in the morbidly obese and control groups, respectively. T0 was determined 177±23 s, 168±19 s in the morbidly obese, and control group, respectively. T25 was determined 46±7 min, 56±8 min, in the morbidly obese and control group, respectively (p<0.05). T25-75 was determined 11±5 min, 14±6 min in the morbidly obese and control group, respectively (p<0.05). In the morbidly obese group, intubation conditions were determined good in 13 patients, excellent in 7 patients, and it were good in 4, excellent in 16 in the control group (p<0.05). When compared to normal weight patients, neuromuscular effects of cisatracurium detected to be short in duration in morbidly obese patients.

Keywords:

Drug Administration Schedule, Atracurium, Neuromuscular Blockade, Obesity, Morbid, Body Mass Index, Intubation,

PDF

___

1. Bray GA. Definitions, measurements and classifications of the syndromes of obesity. Int J Obes 1978; 2:99-112.
2. Bray GA. Classification and evaluation of obesities. Med Clin North Am 1989; 73: 161-84.
3. Kayhan Z. Klinik Anestezi, İstanbul, Logos yayıncılık, 1997; 618-20.
4. National Institutes of Health Consensus Development Conference Statement. Gastrointestinal surgery for severe obesity. Ann Intern Med 1991; 115:956-61.
5. Bentley JB, Borel JD, Vaughan RW, Gandolfy JA. Weight, pseudocholinesterase activity and succinylcholine requirement. Anesthesiology 1982; 57:48-9.
6. Cooper JR, Brodsky JB. Anesthetic management of the morbidly obese patient. Seminars in Anesthesia 1987; 6:260-70.
7. Eriksen J, Andersen J, Rasmussen JP. Postoperative pulmonary function in obese patients after upper abdominal surgery. Acta Anaesthesiol Scand 1977; 21:336-41.
8. Fox GS, Whalley DG, Bevan OR. Anaesthesia for the morbidly obese: Experience with 110 patients. Br J Anesth 1981; 53:811-6.
9. Schwartz AE, Mattwo RS, Ornstein E, Chuw FT, Diaz J. Pharmacokinetics and dynamics of metocurine in the obese. Anesthesiology 1986; 65:A295.
10. Tsueda, Warren JE, Mc Cafferty LA, Nagle JP. Pancuronium bromide requirement during anesthesia for the morbidly obese. Anesthesiology 1978; 48:438-9.
11. Varin F, Ducharme J, Theoret Y, Besner JG, Bevan DR, Donati F. Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. Clin Pharmacol Ther 1990; 48:18-25.
12. Weinstein JA, Matteo RS, Ornstein E, Schwartz AE, Goldstoff M, Thal G. Pharmacodynamics of vecuronium and atracurium in the obese surgical patient. Anesth Analg 1988; 67:1149-53.
13. Miller Rd, Katzung BG. Skeletal muscle relaxants In Katzung BG, (ed) Basic&clinical pharmacology. USA:The McGraw-Hill companies 2001:446-62.
14. Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR. Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996; 83: 1065-71.
15. Shenkman Z, Shir Y, Brodsky JB. Perioperative management of the obese patient. Br J Anaesth 1993;70: 349-59.
16. Servin F, Farinotti R, Haberer JP, Desmonts JM. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology 1993; 78:657-65.
17. Viby-Mogensen J, Engbaek J, Eriksson LI, et al. Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scand 1996; 40:59-74.
18. Alvarez AO, Albarracin Menendez S,Capria JJ, Cordero RA. Total intravenous anesthesia with midazolam, remifentanil, propofol and cisatracurium in morbid obesity. Obes Surg 2000; 10: 353-60.
19. Suzuki T, Munakata K, Watanabe N, Katsumata N, Saeki S, Ogawa S. Augmentation of vecuronium-induced neuromuscular block during sevoflurane anaesthesia: comparison with balanced anaesthesia using propofol or midazolam. Br J Anaesth 1999; 83: 485-7.
20. Elar Z, Özzeybek D.Obezite ve anestezi. Prof. Dr. C. Yılmaz (editör) Obezite. Nobel Tıp Kitapevi 1995; 215-66.